Invion

Subscribe to receive announcements and updates from Invion.

Home

Announcements

Updates

New investors

Lato

No adverse events identified by the Safety Review Committee (SRC) following the treatment of the first six patients in Invion’s Phase I/II non-melanoma skin cancer (NMSC) trial

Early indications show an observable reduction in the NMSC lesion size after a single treatment cycle

Clinician feedback indicated that patients did not experience any pain during the treatment, which compares favourably to currently approved PDT treatments

The early results also highlighted INV043’s potential as a diagnostic with suspected cancers fluorescing under violet light

Proceeding to Part 2 of the adaptive trial that will enable further dose optimisation permitted under the protocol

The safety data is also an important input into the upcoming Ph I/II anogenital trial done in partnership with the Peter MacCallum Cancer Centre